HCM

HUTCHMED (China) Limited - ADR

15.22

USD

HCM Earnings Reports

Positive Surprise Ratio

HCM beat 5 of 5 last estimates.

100%

Next Report

Date of Next Report

Aug 05, 2026

Estimate for Q2 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q2 25 (Revenue/ EPS)

HUTCHMED (China) Limited - ADR earnings per share and revenue

On Mar 17, 2026, HCM reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q2 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Palvella Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.92

Actual

-$1.08

Surprise

-16.19%

Bicara Therapeutics Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.68

Actual

-$0.68

Surprise

+0.66%

Neumora Therapeutics, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.33

Actual

-$0.35

Surprise

-5.39%

DiaMedica Therapeutics Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.17

Surprise

+7.41%

Sangamo Therapeutics, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-14.38%

RenovoRx, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.08

Surprise

+1.96%

INmune Bio Inc. Common stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.26

Actual

-$0.18

Surprise

+32.13%

PDS Biotechnology Corporation Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.14

Surprise

+27.76%

VolitionRX Limited Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.05

Surprise

-17.65%

Lantern Pharma Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.36

Surprise

+23.27%

FAQ

What were HUTCHMED (China) Limited - ADR's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, HUTCHMED (China) Limited - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to HUTCHMED (China) Limited - ADR's Q4 2025 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is HUTCHMED (China) Limited - ADR expected to report next?

The next earning report is scheduled for Aug 05, 2026.

What are the forecasts for HUTCHMED (China) Limited - ADR's next earnings report?

Based on -- analysts, HUTCHMED (China) Limited - ADR is expected to report EPS of -- and revenue of -- for Q2 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.